Evolus Expands Management Team with Appointment of Michael Mazen Jafar as Chief Marketing Officer
June 18 2018 - 8:01AM
Evolus, Inc. (NASDAQ:EOLS) (“Evolus” or the “Company”), a company
dedicated to aesthetic medicine, today announced the expansion of
its management team with the appointment of Michael Mazen Jafar as
Chief Marketing Officer. Mr. Jafar joins Evolus from Allergan where
he most recently served as Vice President, Medical Aesthetics.
At Allergan Mr. Jafar led the commercial launch of Juvederm
Voluma®, which has been recognized as not only one of the largest
launches in the medical aesthetics category, but also the most
successful, as measured by year one sales. He also led product
development and marketing initiatives for the Botox® Cosmetic,
Juvederm®, Kybella®, Latisse®, and Natrelle® franchises at
Allergan. His most recent role at Allergan was to lead
the market assessment and subsequent integration of
the CoolSculpting® franchise acquired from Zeltiq.
Mr. Jafar has more than a decade of product development,
upstream and downstream marketing, and commercial assessment
experience and has launched several direct-to-consumer campaigns
and market transformational initiatives.
David Moatazedi, President and Chief Executive Officer of
Evolus, stated, “I am pleased to announce another exceptional
addition to our management team as we continue to evaluate our
value proposition and expand our world class commercial
infrastructure ahead of the anticipated launch of our lead product
candidate, DWP-450. I am confident that Mike will have an immediate
impact on our organization and bring a fresh perspective to our
team as we further develop and execute our commercial
strategy.”
Michael Jafar, Chief Marketing Officer, said, “Evolus represents
an unparalleled opportunity to build a premier aesthetics-only
franchise while developing a dynamic and customer centric platform
company to best penetrate the large and growing cash-pay aesthetics
market. I am excited to leverage my diverse skill set, market
knowledge, and broad experience in bringing novel products to
market to drive the commercial success of DWP-450 upon regulatory
approval.”
Prior to his move into medical aesthetics,
Mr. Jafar held a number of roles of increasing
responsibility in Allergan’s ophthalmic division. Mr. Jafar
holds an MBA from the University of Southern California and a BA
with an emphasis on international finance and supply chain
management from the University of San Diego.
About Evolus, Inc.
Evolus is a company dedicated to aesthetic medicine focused on
providing physicians and their patients with expanded choices in
aesthetic treatments and procedures. Evolus’ lead candidate
DWP-450, also known by the chemical name prabotulinumtoxinA, is a
900 kDa purified botulinum toxin type A complex that is being
evaluated for the treatment of moderate to severe glabellar
lines.
Forward-Looking Statements
Statements made in this press release that relate to future
plans, events, prospects or performance are forward-looking
statements as defined under the Private Securities Litigation
Reform Act of 1995. All statements, other than statements of
historical fact, are statements that could be deemed
forward-looking statements, including statements containing the
words "planned," "expect," "believes," "strategy," "opportunity,"
"anticipates," "outlook," "designed," and similar words.
While these forward-looking statements are based on the current
expectations and beliefs of management, such forward-looking
statements are subject to a number of risks, uncertainties,
assumptions and other factors that could cause actual results to
differ materially from the expectations expressed in this press
release, including the risks and uncertainties disclosed in Evolus’
periodic filings with the Securities and Exchange Commission,
including factors described in the section entitled "Risk Factors"
in its Annual Report on Form 10-K for the year ended December 31,
2017 and its Quarterly Report on Form 10-Q for the Quarter ended
March 31, 2018, as filed with the Securities and Exchange
Commission on March 29, 2018 and May 10, 2018, respectively, all of
which are available online at www.sec.gov. Readers are cautioned
not to place undue reliance on these forward-looking statements,
which speak only as of the date hereof. Except as required by law,
Evolus undertakes no obligation to update or revise any
forward-looking statements to reflect new information, changed
circumstances or unanticipated events.
Evolus Contacts:
Investor Contact:Brian Johnston, The Ruth Group Tel: +1
646-536-7028Email: IR@Evolus.com
Media:Kirsten Thomas, The Ruth GroupTel: +1-508-280-6592Email:
kthomas@theruthgroup.com
CoolSculpting® is a registered trademark of Zeltiq Aesthetics,
Inc.Juvederm Voluma®, Botox®, Latisse®, and Natrelle® are
registered trademarks of Allergan, Inc.Kybella® is a registered
trademark of Kythera Biopharmaceuticals, Inc.
Evolus (NASDAQ:EOLS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Evolus (NASDAQ:EOLS)
Historical Stock Chart
From Apr 2023 to Apr 2024